TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics Ltd has announced a deferral of its 2025 Annual General Meeting (AGM) to 28 February 2026, following an extension granted by the Australian Securities and Investments Commission. This decision comes after a series of board changes, including the resignation of two directors and the appointment of new non-executive directors. The company plans to issue a new notice of meeting to address the re-election of current directors and the election of new board members, reflecting its ongoing governance adjustments.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company specializing in the repurposing of the approved drug Exenatide for treating neurological conditions associated with raised intracranial pressure. The company has trademarked its repurposed Exenatide as Presendin™.
Average Trading Volume: 69,222
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$9.77M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.